Clomipramine

Pronunciation: kloe-MIP-ra-meen.

Generic name
clomipramine hydrochloride
Brand names
Anafranil (most countries), APO-Clomipramine, Clomipramine-Teva, Clomipramine-WGR (generic, various countries)
Drug class
Tricyclic antidepressant (TCA) with potent serotonin-reuptake-inhibiting activity
Form
Capsule or tablet, 10 mg, 25 mg, 50 mg, or 75 mg depending on brand and market
Route
Oral
Legal status
Prescription-only in all markets reviewed.

Availability and supply rules vary by country

Trade names by country: United States · United Kingdom · Canada · Australia · New Zealand

Australia: Anafranil (5), APO-Clomipramine (5) · Full directory

What clomipramine hydrochloride is and how it works

Clomipramine is a tricyclic antidepressant that increases the amount of certain natural chemical messengers (mainly serotonin, and to a lesser extent noradrenaline) in the brain. In the United States it is approved specifically for obsessive-compulsive disorder (OCD); in the United Kingdom and several other countries it is also approved for depression, obsessional and phobic states, and as an add-on treatment for cataplexy in narcolepsy. (1) (2)

Like all antidepressants, clomipramine carries a genuine boxed warning for an increased risk of suicidal thinking and behaviour in children, adolescents, and young adults under 25, especially in the first few months of treatment and after dose changes -- close monitoring by family, caregivers, and the prescriber is essential during this time. Clomipramine also carries a real, dose-related seizure risk, a serious risk of drug interactions with MAOI antidepressants and other serotonergic medicines, and effects on heart rhythm -- always take it exactly as prescribed and never stop or change your dose without your prescriber's guidance, since stopping abruptly can cause withdrawal symptoms.

Mechanism of action: how clomipramine hydrochloride works

Clomipramine is a tricyclic antidepressant that potently inhibits neuronal reuptake of serotonin (and, via its active desmethyl-metabolite, noradrenaline), increasing synaptic availability of these neurotransmitters. It also has anticholinergic, antihistaminic, and alpha-adrenergic-blocking activity, accounting for much of its side-effect profile. (1) (2)

What clomipramine hydrochloride is used for

Obsessive-compulsive disorder (OCD)

Treats obsessions and compulsions in OCD that cause marked distress, take up significant time, or significantly interfere with social or work functioning. This is the sole approved US indication. (1)

Depression

Treats symptoms of depressive illness, particularly where a sedating antidepressant is appropriate. (2)

Obsessional and phobic states

Treats obsessional and phobic states, similar to the OCD indication approved in the United States. (2)

Cataplexy associated with narcolepsy (add-on treatment)

Used as an adjunctive (add-on) treatment for cataplexy -- sudden muscle weakness triggered by strong emotion -- in people with narcolepsy. (2)

Before taking clomipramine hydrochloride

Do not take / not appropriate for

  • Do not take clomipramine if you have taken a monoamine oxidase inhibitor (MAOI) antidepressant in the last 2-3 weeks, or if you plan to start one -- this combination is contraindicated because of a serious risk of serotonin syndrome and hypertensive crisis. (all countries) (1) (2)
  • Do not take clomipramine if you have recently had a heart attack, have heart block, or have a cardiac arrhythmia. (United Kingdom, European Union) (2) (1)
  • Do not take clomipramine if you have narrow-angle glaucoma, urinary retention, mania, or severe liver disease. (United Kingdom, European Union) (2)
  • Do not take clomipramine with linezolid or intravenous methylene blue. (United States) (1)
  • Do not take clomipramine if you have a known allergy to clomipramine or other tricyclic antidepressants. (all countries) (1) (2)

Tell your clinician about

  • Any personal or family history of seizures, or any condition that increases seizure risk.
  • Any heart problems, including irregular heartbeat, heart block, or a recent heart attack.
  • Any history of glaucoma, urinary retention, or difficulty emptying your bladder.
  • Any personal or family history of bipolar disorder or mania.
  • All other medicines and supplements you take, especially other antidepressants (including SSRIs and other TCAs), MAOIs, triptans, tramadol, lithium, and St John's Wort, since these increase the risk of serotonin syndrome.
  • Whether you are pregnant, plan to become pregnant, or are breastfeeding.
  • Whether you or a family member has ever had thoughts of suicide or self-harm.
(1) (2)

How to take clomipramine hydrochloride

  • Take clomipramine exactly as your prescriber directs -- your dose is started low and increased gradually over the first few weeks.
  • Doses are often taken with meals during the titration period, and the full daily dose may be taken once at bedtime after titration, since it can cause drowsiness.
  • Do not stop taking clomipramine suddenly without talking to your prescriber -- abrupt discontinuation can cause withdrawal symptoms such as dizziness, nausea, vomiting, headache, sleep disturbance, and irritability. Your prescriber will taper your dose gradually if you need to stop.
  • It may take several weeks of treatment before you notice the full benefit.
(1) (2)

Procedures and treatment changes

Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1) (2) (3) (4) (5) (6)

Missed dose

If you miss a dose, contact your pharmacist or prescriber for guidance rather than doubling your next dose. Do not stop or change your dosing schedule on your own.

Overdose

Clomipramine overdose can be fatal and requires emergency medical attention immediately, even if you feel well at first -- symptoms can appear within 4 hours and peak around 24 hours later, with risk continuing for several days. Call emergency services or go to the nearest emergency department right away; in the United States, you can also contact a poison control centre at 1-800-222-1222. (1) (2)

Side effects

Side effects and their urgency vary; report severe, persistent, or concerning symptoms.

Dry mouth -- very common, affecting the majority of patients.

What to notice: Dry mouth -- very common, affecting the majority of patients.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1) (2)

Drowsiness (somnolence) and tremor.

What to notice: Drowsiness (somnolence) and tremor.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1) (2)

Dizziness and headache.

What to notice: Dizziness and headache.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1) (2)

Constipation and nausea.

What to notice: Constipation and nausea.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1) (2)

Weight gain and increased appetite.

What to notice: Weight gain and increased appetite.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1) (2)

Sexual side effects, including ejaculatory failure and erectile dysfunction in men.

What to notice: Sexual side effects, including ejaculatory failure and erectile dysfunction in men.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1) (2)

Serious warnings

Suicidal thoughts or worsening mood, especially in young people — boxed_warning

Symptoms: New or worsening depression, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, restlessness, unusual behaviour changes, or thoughts of suicide or self-harm.

Action: Contact the prescriber immediately, especially if these appear suddenly or are severe -- this risk is highest in children, adolescents, and young adults under 25, particularly in the first few months of treatment and after any dose change. Family members and caregivers should watch closely during this time. (1)

Seizures — high caution

Symptoms: A seizure or convulsion.

Action: Seek emergency medical help immediately. Clomipramine has a real, dose-related seizure risk (up to about 1.45% of patients by one year of treatment at higher doses), which is why the dose is capped and increased gradually -- tell your prescriber about any personal or family history of seizures before starting. (1)

Serotonin syndrome — emergency

Symptoms: Agitation, confusion, rapid heartbeat, high blood pressure, dilated pupils, muscle twitching or rigidity, sweating, diarrhoea, fever, or seizures.

Action: Seek emergency medical help immediately -- this is a potentially life-threatening reaction, most likely when clomipramine is combined with other serotonergic medicines (such as MAOIs, SSRIs, triptans, tramadol, lithium, or St John's Wort). Tell every prescriber about all medicines and supplements you take. (1) (2)

Heart rhythm changes (QT prolongation, arrhythmia) — high caution

Symptoms: A fast, irregular, or pounding heartbeat, chest pain, or fainting.

Action: Seek prompt medical attention -- clomipramine can affect heart rhythm, and this risk is higher with existing heart disease, electrolyte imbalances (such as low potassium), or other medicines that affect heart rhythm. (1) (2)

Sudden eye pain or vision changes (possible angle-closure glaucoma) — emergency

Symptoms: Sudden eye pain, blurred vision, or seeing halos around lights.

Action: Seek emergency eye care immediately -- clomipramine can trigger an angle-closure glaucoma attack in people with anatomically narrow eye drainage angles. (1)

Manic or hypomanic episode — high caution

Symptoms: Unusually elevated mood, decreased need for sleep, racing thoughts, or reckless behaviour.

Action: Contact your prescriber promptly -- clomipramine can trigger a manic episode in people with an underlying mood disorder. (1)

Interactions

  • MAOI antidepressants must never be combined with clomipramine, and at least 2-3 weeks should separate stopping one and starting the other, because of a serious risk of serotonin syndrome and hypertensive crisis. (1) (2)
  • SSRIs and other serotonergic antidepressants can substantially raise clomipramine levels (up to several-fold) and add to serotonin syndrome risk; a washout period is recommended when switching between clomipramine and fluoxetine specifically. (1) (2)
  • Other CYP2D6-inhibiting medicines can also raise clomipramine and its active metabolite to substantially higher levels, requiring dose adjustment by the prescriber. (1)
  • Medicines that prolong the QT interval, or that cause low potassium (such as some diuretics), increase the risk of dangerous heart rhythm changes when combined with clomipramine. (2)
  • Rifampicin, certain anticonvulsants, and smoking can reduce clomipramine's effectiveness by lowering its blood levels. (2)
  • Other medicines with anticholinergic or sedating effects can add to clomipramine's dry mouth, drowsiness, and related effects. (2)

Pregnancy, breastfeeding, kidney/liver function, age

Pregnancy

Clomipramine is not recommended during pregnancy or in people who could become pregnant and are not using contraception, based on limited human data (including a slightly increased rate of cardiac birth defects in one registry study) and evidence of neonatal withdrawal symptoms (breathing difficulty, lethargy, irritability, tremor, blood pressure changes) when taken late in pregnancy. Discuss the risks and benefits with your prescriber before starting or continuing. (1) (2) (3) (4) (5) (6)

Breastfeeding

Clomipramine passes into breast milk in small amounts; discuss with your prescriber whether to continue breastfeeding or continue the medicine. (1) (2) (3) (4) (5) (6)

Children

Approved for OCD in children and adolescents aged 10-17 in the United States; not established for children under 10, and not recommended for any indication in people under 18 in the reviewed UK labelling. The boxed warning for suicidality risk applies with particular importance in this age group. (1) (2) (3) (4) (5) (6)

Elderly

Older adults are usually started on a lower dose and increased more cautiously; short-term studies actually showed a reduced suicidality risk with antidepressants in adults 65 and older, but other risks (falls, confusion, heart effects) may need closer monitoring in this age group. (1) (2) (3) (4) (5) (6)

Hepatic_impairment

Severe liver disease is a contraindication in the reviewed UK labelling; use with caution and closer monitoring in any degree of liver impairment. (1) (2) (3) (4) (5) (6)

Renal_impairment

Use with caution in kidney impairment; no specific dose-adjustment schedule was identified in the sources reviewed for this dossier. (1) (2) (3) (4) (5) (6)

Source_ids

US-DAILYMED-ANAFRANIL-2026,UK-EMC-CLOMIPRAMINE-25MG-2026 (1) (2) (3) (4) (5) (6)

Monitoring

Before starting

  • Screening for seizure history, heart disease, glaucoma, urinary retention, and personal/family history of mania or suicidality
  • Review of all other medicines, especially MAOIs, SSRIs, and other serotonergic or QT-prolonging medicines
  • Baseline electrolytes (especially potassium) where cardiac risk factors are present

During treatment

  • Close monitoring for suicidality, mood changes, and unusual behaviour, especially in the first few months and after dose changes, particularly in patients under 25.
  • Periodic cardiac monitoring (and ECG where indicated) during longer-term therapy, especially with pre-existing heart disease.
  • Regular reassessment of continued need for treatment and dose.
(1) (2)

Storage

Store at controlled room temperature (20-25degC/68-77degF in the US label; below 25degC in the UK SmPC) in a well-closed, child-resistant container, protected from moisture, out of reach of children.

Professional information

Clinician-facing context only, sourced from the current US FDA Anafranil prescribing information and current UK emc Clomipramine 25 mg SmPC; verify against the current full local label before prescribing.

United States

Indication: Obsessive-compulsive disorder (OCD)

Dose summary: Adults: start 25 mg daily, titrate to ~100 mg over 2 weeks, then up to a maximum of 250 mg daily. Children/adolescents 10-17 (OCD only): start 25 mg daily, titrate over 2 weeks to 3 mg/kg or 100 mg (whichever smaller), maximum 3 mg/kg or 200 mg (whichever smaller).

Renal context: No specific US renal dose-adjustment schedule identified in the sources reviewed. (1)

United Kingdom / European Union / Canada / Australia / New Zealand

Indication: Depression, obsessional/phobic states, adjunctive cataplexy

Dose summary: Adults: start 10 mg daily, titrate to 30-150 mg daily (up to 250 mg for obsessional/phobic states); maintenance typically 30-50 mg daily. Elderly: start 10 mg daily, titrate cautiously to an optimum of 30-75 mg daily over about 10 days. Cataplexy: 10-75 mg daily.

Renal context: Use with caution in renal impairment; no specific dose-adjustment schedule identified in the sources reviewed. (2)

Mechanism of action

Hepatic guidance

Severe hepatic impairment is a contraindication per the reviewed UK labelling; use with caution and enhanced monitoring in any degree of liver impairment.

Overdose note

No specific antidote exists; overdose management is symptomatic and supportive, with immediate ECG/cardiac monitoring, airway protection, gastric decontamination where appropriate, sodium bicarbonate for cardiac conduction abnormalities, and benzodiazepines for seizures. Haemodialysis and peritoneal dialysis are generally ineffective given clomipramine's high protein binding and large volume of distribution. (1) (2)

Frequently asked questions

Does clomipramine have a boxed warning?

Yes. Clomipramine's current US FDA label carries a boxed warning -- shared with antidepressants as a class -- for an increased risk of suicidal thinking and behaviour in children, adolescents, and young adults under 25 during short-term treatment, especially in the first few months and after dose changes. Close monitoring by family, caregivers, and the prescriber is essential during this time. (1)

Can I take clomipramine with an MAOI antidepressant?

No. Combining clomipramine with an MAOI antidepressant is contraindicated because of a serious risk of serotonin syndrome and hypertensive crisis. At least 2-3 weeks should separate stopping one and starting the other -- always follow your prescriber's specific switching instructions. (1) (2)

Why does my dose have a maximum limit?

Clomipramine carries a real, dose-related seizure risk -- the cumulative chance of a seizure rises with both dose and duration of treatment. The maximum recommended doses (250 mg daily for adults; 3 mg/kg or 200 mg for children/adolescents) exist specifically to manage this risk, so never exceed your prescribed dose. (1)

Can I stop taking clomipramine suddenly?

No. Stopping clomipramine abruptly can cause withdrawal symptoms such as dizziness, nausea, vomiting, headache, sleep disturbance, and irritability. If you and your prescriber decide you should stop, your dose will usually be tapered down gradually. (2)

What is the mechanism of action of clomipramine hydrochloride?

Clomipramine is a tricyclic antidepressant that potently inhibits neuronal reuptake of serotonin (and, via its active desmethyl-metabolite, noradrenaline), increasing synaptic availability of these neurotransmitters. It also has anticholinergic, antihistaminic, and alpha-adrenergic-blocking activity, accounting for much of its side-effect profile. (1) (2)

What is the generic name of Clomipramine?

The generic name is clomipramine hydrochloride. It is sold under brand names including Anafranil (most countries), APO-Clomipramine, Clomipramine-Teva, Clomipramine-WGR (generic, various countries). (1) (2)

What class of drug is clomipramine hydrochloride?

Clomipramine is classed as: Tricyclic antidepressant (TCA) with potent serotonin-reuptake-inhibiting activity. (1) (2)

References

  1. ANAFRANIL (clomipramine hydrochloride) capsules -- full prescribing informationU.S. Food and Drug Administration / DailyMed (NIH), full prescribing information · United States · accessed 2026-07-30 · source 1
  2. Clomipramine 25 mg Capsules, Hard -- Summary of Product Characteristicselectronic medicines compendium (emc), United Kingdom -- Viatris (Generics [UK] Ltd t/a Mylan) · United Kingdom · accessed 2026-07-30 · source 2
  3. Clomipramine -- list of nationally authorised medicinal products (PSUSA/00000811/202503)European Medicines Agency (EMA) -- list of nationally authorised medicinal products (PSUSA procedure) · European Union · accessed 2026-07-30 · source 3
  4. ANAFRANIL (clomipramine hydrochloride) and APO-CLOMIPRAMINE -- Product MonographsHealth Canada product monograph · Canada · accessed 2026-07-30 · source 4
  5. ANAFRANIL clomipramine hydrochloride 25 mg tablet blister pack -- ARTG entry 10987Therapeutic Goods Administration (TGA), Australia · Australia · accessed 2026-07-30 · source 5
  6. APO-CLOMIPRAMINE and Clomipramine-Teva -- New Zealand Data SheetsMedsafe (New Zealand regulator) · New Zealand · accessed 2026-07-30 · source 6

Brand names by country

Single-ingredient clomipramine hydrochloride names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.

Priority countries

United States

  • ANAFRANIL25 mg, 75 mg, 50 mg · specgx llc

United Kingdom

  • Clomipramine (generic) (2)MHRA licensed emc smpc confirmed · 10 mg, 25 mg, 50 mg · Generics [UK] Ltd t/a Mylan (Viatris)

Canada

  • ANAFRANIL

Australia

  • Anafranil (5)TGA ARTG registered 1991-08-02 · 25 mg · Pharmaco Australia Ltd
  • APO-Clomipramine (5)TGA ARTG registered 2000-06-07 · 25 mg · Arrotex Pharmaceuticals Pty Ltd

New Zealand

  • APO-Clomipramine (6)Medsafe data sheet located · 25 mg · not independently confirmed beyond data-sheet existence in this pass
  • Clomipramine-Teva (6)Medsafe data sheet located · 10 mg, 25 mg · Teva
View brands in additional countries.

European Union

Anafranil (and generics) (3)

This page provides general reference information about clomipramine and is not a substitute for advice from the prescriber managing your treatment. All dosing and treatment decisions, including starting, changing, or stopping this medicine, should be made with your prescriber.

Related medicines

Related conditions